Why the study?
Activation of the NLRP3 inflammasome is instrumental in inflammation and may cause atherosclerosis, making it a promising therapeutic target.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
NLRP3 inflammasome activation may promote atherosclerosis; leaves open targeted therapy trials.
Inflammation is an intricate biological response of body tissues to detrimental stimuli. Cardiovascular disease (CVD) is the leading cause of death worldwide, and inflammation is well documented to play a role in the development of CVD, especially atherosclerosis (AS). Emerging evidence suggests that activation of the NOD-like receptor (NLR) family and the pyridine-containing domain 3 (NLRP3) inflammasome is instrumental in inflammation and may result in AS. The NLRP3 inflammasome acts as a molecular platform that triggers the activation of caspase-1 and the cleavage of pro-interleukin (IL)-1β, pro-IL-18, and gasdermin D (GSDMD). The cleaved GSDMD forms pores in the cell membrane and initiates pyroptosis, inducing cell death and the discharge of intracellular pro-inflammatory factors. Hence, the NLRP3 inflammasome is a promising target for anti-inflammatory therapy against AS. In this review, we systematically summarized the current understanding of the activation mechanism of NLRP3 inflammasome, and the pathological changes in AS involving NLRP3. We also discussed potential therapeutic strategies targeting NLRP3 inflammasome to combat AS.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: